Kairos Pharma's KROS101 Shows Promise in Cancer Immunotherapy at ASCO 2025
Kairos Pharma presents KROS101 data at ASCO 2025, showcasing potential in cancer immunotherapy. Discover how this could change treatment paradigms.
This news is significant as it highlights a potential breakthrough in cancer treatment, offering hope for patients with resistant forms of cancer. KROS101's dual mechanism could pave the way for more effective immunotherapies, addressing a critical need in oncology. The advancement of ENV105 also represents a promising avenue for overcoming drug resistance, a major challenge in cancer therapy today.